These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22196155)

  • 1. Acid phosphatase-positive globular inclusions is a good diagnostic marker for two patients with adult-onset Pompe disease lacking disease specific pathology.
    Tsuburaya RS; Monma K; Oya Y; Nakayama T; Fukuda T; Sugie H; Hayashi YK; Nonaka I; Nishino I
    Neuromuscul Disord; 2012 May; 22(5):389-93. PubMed ID: 22196155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed or late-onset type II glycogenosis with globular inclusions.
    Sharma MC; Schultze C; von Moers A; Stoltenburg-Didinger G; Shin YS; Podskarbi T; Isenhardt K; Tews DS; Goebel HH
    Acta Neuropathol; 2005 Aug; 110(2):151-7. PubMed ID: 15986226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rigid spine syndrome revealing late-onset Pompe disease.
    Laforêt P; Doppler V; Caillaud C; Laloui K; Claeys KG; Richard P; Ferreiro A; Eymard B
    Neuromuscul Disord; 2010 Feb; 20(2):128-30. PubMed ID: 20005713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel mutation of the GAA gene in a patient with adult-onset Pompe disease lacking a disease-specific pathology.
    Fujimoto S; Manabe Y; Fujii D; Kozai Y; Matsuzono K; Takahashi Y; Narai H; Omori N; Adachi K; Nanba E; Nishino I; Abe K
    Intern Med; 2013; 52(21):2461-4. PubMed ID: 24190153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.
    Young SP; Piraud M; Goldstein JL; Zhang H; Rehder C; Laforet P; Kishnani PS; Millington DS; Bashir MR; Bali DS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):50-8. PubMed ID: 22252961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of acid phosphatase positivity and rimmed vacuoles as useful markers in the diagnosis of adult-onset Pompe disease lacking specific clinical and pathological features.
    Dolfus C; Simon JP; Landemore G; Leroy F; Chapon F
    Folia Neuropathol; 2016; 54(3):295-302. PubMed ID: 27764522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited.
    Schoser BG; Müller-Höcker J; Horvath R; Gempel K; Pongratz D; Lochmüller H; Müller-Felber W
    Neuropathol Appl Neurobiol; 2007 Oct; 33(5):544-59. PubMed ID: 17573812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies.
    Preisler N; Lukacs Z; Vinge L; Madsen KL; Husu E; Hansen RS; Duno M; Andersen H; Laub M; Vissing J
    Mol Genet Metab; 2013 Nov; 110(3):287-9. PubMed ID: 24011652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
    Kroos MA; Pomponio RJ; Hagemans ML; Keulemans JL; Phipps M; DeRiso M; Palmer RE; Ausems MG; Van der Beek NA; Van Diggelen OP; Halley DJ; Van der Ploeg AT; Reuser AJ
    Neurology; 2007 Jan; 68(2):110-5. PubMed ID: 17210890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Periodic acid-Schiff staining on resin muscle sections: improvement in the histological diagnosis of late-onset Pompe disease.
    Terracciano C; Rastelli E; Massa R
    Muscle Nerve; 2012 Apr; 45(4):611-2. PubMed ID: 22431097
    [No Abstract]   [Full Text] [Related]  

  • 11. Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease.
    Umapathysivam K; Hopwood JJ; Meikle PJ
    Clin Chim Acta; 2005 Nov; 361(1-2):191-8. PubMed ID: 15993875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.
    Goldstein JL; Young SP; Changela M; Dickerson GH; Zhang H; Dai J; Peterson D; Millington DS; Kishnani PS; Bali DS
    Muscle Nerve; 2009 Jul; 40(1):32-6. PubMed ID: 19533645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy.
    Papadimas GK; Spengos K; Konstantinopoulou A; Vassilopoulou S; Vontzalidis A; Papadopoulos C; Michelakakis H; Manta P
    Clin Neurol Neurosurg; 2011 May; 113(4):303-7. PubMed ID: 21216089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic criteria for late-onset (childhood and adult) Pompe disease.
    American Association of Neuromuscular & Electrodiagnostic Medicine
    Muscle Nerve; 2009 Jul; 40(1):149-60. PubMed ID: 19533647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pompe disease (glycogen storage disease type II) in Argentineans: clinical manifestations and identification of 9 novel mutations.
    Palmer RE; Amartino HM; Niizawa G; Blanco M; Pomponio RJ; Chamoles NA
    Neuromuscul Disord; 2007 Jan; 17(1):16-22. PubMed ID: 17056254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A retrospective study of six patients with late-onset Pompe disease].
    Saux A; Laforet P; Pagès AM; Figarella-Branger D; Pellissier JF; Pagès M; Labauge P
    Rev Neurol (Paris); 2008 Apr; 164(4):336-42. PubMed ID: 18439925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy.
    Cho A; Kim SJ; Lim BC; Hwang H; Park JD; Kim GB; Jin DK; Lee J; Ki CS; Kim KJ; Hwang YS; Chae JH
    J Child Neurol; 2012 Mar; 27(3):319-24. PubMed ID: 21940687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the acid alpha-glucosidase gene (M. Pompe) in a patient with an unusual phenotype.
    Anneser JM; Pongratz DE; Podskarbi T; Shin YS; Schoser BG
    Neurology; 2005 Jan; 64(2):368-70. PubMed ID: 15668445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.
    Katzin LW; Amato AA
    J Clin Neuromuscul Dis; 2008 Jun; 9(4):421-31. PubMed ID: 18525427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pompe's disease. Part I: pathogenesis and clinical features].
    Illés Z; Trauninger A
    Ideggyogy Sz; 2009 Jul; 62(7-8):231-43. PubMed ID: 19685701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.